Aim Immunotech Inc (AIM) Directors and Executive Officers - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 
Aim Immunotech Inc   (NYSEAMER: AIM)

Aim Immunotech Inc

Officers & Directors


Robert Dickey IV
Chief Financial Officer
BDO USA, P.C.

Nancy Bryan
Director

William Mitchell
Chairman of the Board

Thomas K. Equels
Chief Executive Officer

Stewart L. Appelrouth
Director ,

Aim Immunotech Inc currently has 21 employees.

  News about Aim Immunotech Inc Key Personnel

AIM ImmunoTech Faces Financial Headwinds as It Postpones Offering Amidst Ambitious Healthcare Goals,

AIM ImmunoTech Inc.: Navigating Financial Turbulence Amidst Strategic Ambitions in the Post-COVID Healthcare LandscapeIn a recent press release dated February 11, 2025, AIM ImmunoTech Inc. (NYSE American: AIM) made a crucial announcement concerning its financial offerings. The biotechnology firm revealed that it would be postponing any offering under its Registration Statement on Form S-1 until after it files its Annual Report on Form 10-K for the fiscal year ending December 31, 2024. This decision comes at a pivotal moment as the company grapples with significant financial challenges and seeks to recalibrate its strategic roadmap.AIM ImmunoTech, perhaps best known for its ongoing work on the promising immun...

AIM ImmunoTechs Tumultuous Road: High Hopes vs Historic Losses in the Post-COVID Healthcare Landscape

AIM ImmunoTech s Tumultuous Road: High Hopes vs. Historic Losses in the Post-COVID Healthcare LandscapeAIM ImmunoTech Inc. a biotechnology company known for its work on the immunotherapy drug Ampligen (rintatolimod), has made an ambitious bid for redemption as it navigates the complexities of the post-COVID healthcare era. The company recently released a bullish commentary on its milestones for 2024 and painted an optimistic picture for 2025-26, highlighting its focus on areas with critical unmet medical needs, particularly pancreatic cancer and Long COVID.Yet beneath the surface of its strategic narrative lies a troubling financial reality. For the 12 months ending in the third quarter of 2024, AIM ImmunoTe...

AIM ImmunoTech: Navigating Challenging Financial Terrain with Striving for Breakthroughs

AIM ImmunoTech s Strategic Funding Move Raises Questions Amidst Challenging Financial Performance
In a recent announcement, AIM ImmunoTech Inc. revealed the pricing details of its registered direct offering to raise $2.0 million. The company entered into a securities purchase agreement with a single institutional investor, who agreed to purchase 5,640,958 shares of common stock at a price of $0.363 per share. This offering also includes unregistered Class A and Class B warrants, allowing the investor to purchase additional shares in the future.
These financial maneuvers come at a critical time for AIM ImmunoTech, as recent financial reports indicate a significant cumulative net loss of $-31 million d...

AIM ImmunoTech Advances Clinical Development Program for Advanced Recurrent Ovarian Cancer


In a recent announcement, AIM ImmunoTech Inc. (NYSE American: AIM) disclosed the release of the latest CEO Corner segment, shedding light on the company s clinical development program and its focus on addressing the unmet needs of patients with Advanced Recurrent Ovarian Cancer.
Thomas Equels, the Chief Executive Officer of AIM ImmunoTech, shared insights into the disease s burden and emphasized the urgency to develop effective treatment options. Advanced Recurrent Ovarian Cancer is a challenging condition associated with high rates of recurrence and limited treatment success. Equels highlighted the critical unmet need for innovative therapies that can improve patient outcomes.
As part of its c...






AIM Management Effectiveness AIM Revenue per Employee AIM Income per Employee


Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.